Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers

Nemours opens Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders

Nemours Children’s Health opened the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, on March 19. The institute is a state-of-the-art facility for pediatric patients in the Delaware Valley and beyond.

March 21, 2025

Clinical Roundup

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh developed a new way to profile brain cancers in children.

March 21, 2025

Drugs & Targets

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

March 21, 2025

Regulatory News

Backlog of work grows at NIH as staff members are being hounded to quit

Government work isn’t what it used to be.

March 14, 2025

Vol.51 No.10

By Paul Goldberg, Jacquelyn Cobb and Claire Marie Porter

Drugs & Targets

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA granted Orphan Drug designation to rhenium obisbemeda (186Re) for the treatment of leptomeningeal metastases in patients with lung cancer.

March 14, 2025

Vol.51 No.10

Regulatory News

Trump et al. focus on NIH, cancer—and how peer review is done

In a speech before a joint session of Congress, President Trump briefly addressed pediatric cancer, pointing to a 13-year old brain tumor survivor, Devarjaye “DJ” Daniel, who was watching from the gallery, making his dream come true by naming him a Secret Service agent.

March 07, 2025

Vol.51 No.09

By Jacquelyn Cobb, Claire Marie Porter and Paul Goldberg

Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers

YOU MAY BE INTERESTED IN

Nemours opens Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Backlog of work grows at NIH as staff members are being hounded to quit

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

Trump et al. focus on NIH, cancer—and how peer review is done

Renew today!

Subscriber content

Martha Donoghue named FDA OCE associate director for pediatric oncology and rare cancers

YOU MAY BE INTERESTED IN

Nemours opens Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Backlog of work grows at NIH as staff members are being hounded to quit

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

Trump et al. focus on NIH, cancer—and how peer review is done

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)